Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new glaucoma implant just got the FDA's go-ahead. Ciliatech's Intercil uveal spacer has received an investigational device exemption (IDE), clearing the way for a U.S. feasibility study. The device is designed to fill a gap in the glaucoma treatment ladder — offering more than standard minimally invasive surgery but stopping short of full surgical intervention.
A new glaucoma implant just got the FDA's go-ahead. Ciliatech has secured an FDA investigational device exemption (IDE) for its Intercil uveal spacer, a hydrophilic acrylic implant designed to enhance uveoscleral outflow by creating controlled supraciliary spacing. The company will now launch a U.S. feasibility study evaluating the device's safety and performance in glaucoma patients.
Intercil is positioned as a "middle-ground" option in the glaucoma treatment pathway — intended for patients who need more than traditional minimally invasive glaucoma surgery (MIGS) but aren't yet candidates for more invasive procedures. The device was previously tested in Ciliatech's SAFARI clinical program in Europe, giving the company a head start on safety data.
By the Numbers:
Why it matters: Glaucoma affects millions worldwide, and the treatment landscape has long lacked options between MIGS and major surgery. If Intercil proves safe and effective, it could offer clinicians a meaningful new tool to better tailor treatment to individual patient needs.
